Background: The CHAARTED and LATITUDE trials demonstrated improved outcomes with docetaxel or abiraterone plus androgen deprivation therapy in metastatic hormone sensitive prostate cancer (mHSPC) using two different prognostic scores.
Objective: The aim of our study was to assess the concordance between the two scores and if these retained their prognostic value exclusively in de novo mHSPC.
Patients And Methods: De novo mHSPC patients referring to our institution were retrospectively stratified according to the CHAARTED and LATITUDE classifications: high volume/high risk (HV/HR), low-volume/low-risk (LV/LR), and HVorHR (HV/LR and LV/HR). The Kaplan-Meier method and Cox proportional-hazard models were used to estimate hazard ratios for overall survival.
Results: The study population included 106 patients. Concordance between the CHAARTED and LATITUDE classifications was observed in 86.8% of cases (65.1% HV/HR, 21.7% LV/LR), while 13.2% of patients fulfill the criteria of only one of the two classifications (HVorHR). When analyzed independently, the CHAARTED and LATITUDE classifications maintained their prognostic value (mOS 28.2 months in HV versus 60.9 months in LV, p = 0.006; 28.2 months in HR versus 40.6 months in LR, p = 0.017). The LR/LV population showed significantly longer mOS compared to the HR/HV group (72.6 months versus 26.3 months; p = 0.005), and to HVorHR patients (35.1 months; p = 0.003). No difference in OS was observed between HV/HR and HVorHR patients. ECOG PS ≥ 1 and patient age improved the prognostic value of the two classifications with multivariate analysis.
Conclusions: Our study showed a lack of complete concordance between the CHAARTED and LATITUDE classifications. The analysis confirmed the role of these prognostic scores to stratify de novo mHSPC patients in clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11523-018-0588-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The In-depth Comparative Analysis of Four Large Language AI Models for Risk Assessment and Information Retrieval from Multi-Modality Prostate Cancer Work-up Reports.
World J Mens Health
December 2024
Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei, Taiwan.
Purpose: Information retrieval (IR) and risk assessment (RA) from multi-modality imaging and pathology reports are critical to prostate cancer (PC) treatment. This study aims to evaluate the performance of four general-purpose large language model (LLMs) in IR and RA tasks.
Materials And Methods: We conducted a study using simulated text reports from computed tomography, magnetic resonance imaging, bone scans, and biopsy pathology on stage IV PC patients.
Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer.
Cancers (Basel)
September 2024
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan.
Article Synopsis
- - The treatment approach for metastatic castration-sensitive prostate cancer (mCSPC) has evolved, with androgen receptor signaling inhibitors (ARSI) being the first choice; however, for some Asian patients, androgen deprivation therapy (ADT) and CAB may be more effective.
- - A study of 218 prostate adenocarcinoma patients at Kanazawa University Hospital analyzed risk classification using the Canazawa criteria, which considers factors like Gleason pattern, bone scan index, and LDH levels to better predict outcomes.
- - Results indicated a median overall survival of 85.2 months and a median time to castration resistance of 16.4 months; lower PSA levels after 12 weeks of ADT were linked to
Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy.
Int J Urol
December 2024
Department of Advanced Transplant and Regenerative Medicine, Hirosaki University School of Medicine, Hirosaki, Japan.
Objectives: The objective of this study is to assess the trends in treatment selection for patients with de novo metastatic castration-sensitive prostate cancer in the era of upfront combination therapy.
Methods: This multicenter retrospective study included 595 patients treated with either upfront combination therapy (upfront novel hormonal therapies and taxane-based chemotherapy) or vintage therapy (androgen deprivation therapy with or without bicalutamide) between 2016 and 2021. High tumor burden metastatic disease was defined when a patient met the CHAARTED or LATITUDE criteria.
Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancer.
Prostate
October 2024
Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Background: The first approvals of novel systemic therapies within recent years for metastatic hormone-sensitive (mHSPC) were mainly based on improved overall survival (OS) and time to castration resistance (ttCRPC) in mHSPC patients stratified according to CHAARTED low (LV) versus high volume (HV) and LATITUDE low (LR) versus high-risk (HR) disease.
Methods: Relying on our institutional tertiary-care database we identified all mHSPC stratified according to CHAARTED LV versus HV, LATITUDE LR versus HR and the location of the metastatic spread (lymph nodes (M1a) versus bone (M1b) versus visceral/others (M1c) metastases. OS and ttCRPC analyses, as well as Cox regression models were performed according to different metastatic categories.
Whole-body low-dose CT can be of value in prostate cancer decision-making: a retrospective study on 601 patients.
Insights Imaging
July 2023
Department of Hematology-Oncology, Hematology-Oncology and BMT Research Center/Tehran University of Medical Sciences, Tehran, Iran.
Objectives: To evaluate the diagnostic value of whole-body low-dose computed tomography (CT) to detect bone metastasis in prostate cancer (PCa) patients and its possible utility in therapeutic decision-making. Also, to determine the valuable CT features for lesion characterisation.
Methods: This IRB-approved retrospective study reviewed PCa patients who underwent Ga-PSMA PET/CT in our centre from March 2017 to August 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!